Podcast Atlas
concept Updated 2026-08-06 Topics: Economics

Finite-Game Biotech Competition

Finite-game biotech competition is 大卫翁’s frame in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 for an industry mood shift from open-ended platform breakthrough to more bounded competition inside existing drug categories, assets, and transaction structures. The episode contrasts a prior “infinite game” feeling around PD-1, mRNA, and CAR-T with a 2024-2025 market where companies fight over data increments, pricing, BD terms, and engineering combinations.

The concept is not pessimism alone. It explains why ADC engineering, PD-1/VEGF, TCEs, GLP-1s, and dual-payload ADCs can still matter: mature markets reward better tradeoffs, not only entirely new platforms.

130. 谁才是生物医药行业发展的核心驱动力？兼谈创新药产业链的角色分工 adds the clinical-threshold version of the same frame. The source argues that oncology’s last decade of progress has already moved many major targets and mechanisms into the clinic, so future combinations may face higher survival-benefit, regulatory, and reimbursement bars unless a new PD-1- or CAR-T-scale mechanism appears.

Key Claims

  • Mature therapeutic platforms can still produce valuable products through differentiation and combination.
  • Competition shifts from “does the platform work?” to “who gets enough clinical, manufacturing, cost, and commercial advantage?”
  • BD and capital structure become part of the innovation system when technical novelty is incremental.
  • The frame helps keep enthusiasm and disappointment in the same analysis rather than swinging between boom and winter.
  • Episode 130 adds that mature markets can become harder precisely because earlier success raises the clinical baseline.

Connections